^
    2ms
    A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. (PubMed, Immunotherapy)
    MEDI5083 maximum tolerated dose was 5 mg. Objective response rate was 2.8% (1 partial response and 11 stable disease). MEDI5083 toxicity profile limits its further development.
    P1 data • Journal • Combination therapy • Metastases
    |
    CD40 (CD40 Molecule)
    |
    Imfinzi (durvalumab) • MEDI5083
    over4years
    [VIRTUAL] MEDI5083, a novel CD40L-Fc fusion protein, activates the CD40 pathway on antigen-presenting cells and promotes robust anti-tumor immune responses in both hot and cold murine tumor models (AACR-II 2020)
    We have demonstrated that stimulation of CD40 signaling with MEDI5083 or mCD40L-Fc leads to robust activation of immune cells and enhanced adaptive immune responses. In vivo, this translates to enhanced control of both poorly- and well-infiltrated syngeneic tumors and generation of durable memory in mice with complete tumor regression.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • CD40LG (CD40 ligand)
    |
    MEDI5083